Binding Site appoints new chief financial officer

Binding Site has announced the appointment of Mark Culwick as its new chief financial officer.

Mr Culwick joins the science company having accrued experience in the fields of finance and life science, previously spending a year with the microbiology department of SmithKline Beecham Pharmaceuticals, now GlaxoSmithKline.

His most recent post was that of director at investment banking organisation Rothschild, where he spent a successful 11-year career and helped to found the company's Birmingham office.

Charles de Rohan, the recently-appointed chief executive officer of Binding Site, expressed confidence in the business skills and science background of Mr Culwick.

"His appointment represents a further strengthening of the senior team at Binding Site as we seek to build on the highly successful rollout of Freelite," he added.

Last month, the firm unveiled a newly-developed product called Combylite, a new assay and companion to Freelite that can assist in the monitoring of monoclonal diseases.